213 related articles for article (PubMed ID: 31082785)
21. Clinical implications of imprecise sampling time for 10- and 30-min thyrotropin-releasing hormone stimulation tests in horses.
Vorster DM; Wang W; Kemp KL; Bamford NJ; Bertin FR
Equine Vet J; 2024 Mar; 56(2):291-298. PubMed ID: 37649416
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of combined testing to simultaneously diagnose pituitary pars intermedia dysfunction and insulin dysregulation in horses.
Horn R; Bertin FR
J Vet Intern Med; 2019 Sep; 33(5):2249-2256. PubMed ID: 31498947
[TBL] [Abstract][Full Text] [Related]
23. Single-dose oral pharmacokinetics of pergolide mesylate in healthy adult mares.
Gehring R; Beard L; Wright A; Coetzee J; Havel J; Apley M
Vet Ther; 2010; 11(1):E1-8. PubMed ID: 20949429
[TBL] [Abstract][Full Text] [Related]
24. Circannual variation in plasma adrenocorticotropic hormone concentrations in the UK in normal horses and ponies, and those with pituitary pars intermedia dysfunction.
Copas VE; Durham AE
Equine Vet J; 2012 Jul; 44(4):440-3. PubMed ID: 21848531
[TBL] [Abstract][Full Text] [Related]
25. Circannual variability in adrenocorticotropic hormone responses to administration of thyrotropin-releasing hormone in clinically normal horses in Australia.
Byrne DP; Secombe CJ; Tan RHH; Perera DI; Watts SP; Wearn JG
Vet J; 2018 Aug; 238():58-62. PubMed ID: 30103916
[TBL] [Abstract][Full Text] [Related]
26. Treatment with pergolide or cyproheptadine of pituitary pars intermedia dysfunction (equine Cushing's disease).
Donaldson MT; LaMonte BH; Morresey P; Smith G; Beech J
J Vet Intern Med; 2002; 16(6):742-6. PubMed ID: 12465775
[TBL] [Abstract][Full Text] [Related]
27. Repeatability of a thyrotropin-releasing hormone stimulation test for diagnosis of pituitary pars intermedia dysfunction in mature horses.
Kam YN; McKenzie K; Coyle M; Bertin FR
J Vet Intern Med; 2021 Nov; 35(6):2885-2890. PubMed ID: 34642962
[TBL] [Abstract][Full Text] [Related]
28. Comparison of hair follicle histology between horses with pituitary pars intermedia dysfunction and excessive hair growth and normal aged horses.
Innerå M; Petersen AD; Desjardins DR; Steficek BA; Rosser EJ; Schott HC
Vet Dermatol; 2013 Feb; 24(1):212-7.e46-7. PubMed ID: 23331700
[TBL] [Abstract][Full Text] [Related]
29. Case series of equine pituitary pars intermedia dysfunction in a tropical climate.
Spelta CW; Axon JE
Aust Vet J; 2012 Nov; 90(11):451-6. PubMed ID: 23106327
[TBL] [Abstract][Full Text] [Related]
30. Impact of blue light therapy on plasma adrenocorticotropic hormone (ACTH) and hypertrichosis in horses with pituitary pars intermedia dysfunction.
Miller AB; Murphy BA; Adams AA
Domest Anim Endocrinol; 2022 Jan; 78():106651. PubMed ID: 34656964
[TBL] [Abstract][Full Text] [Related]
31. Factors associated with survival, laminitis and insulin dysregulation in horses diagnosed with equine pituitary pars intermedia dysfunction.
Horn R; Bamford NJ; Afonso T; Sutherland M; Buckerfield J; Tan RHH; Secombe CJ; Stewart AJ; Bertin FR
Equine Vet J; 2019 Jul; 51(4):440-445. PubMed ID: 30417404
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of dynamic testing for pituitary pars intermedia dysfunction diagnosis in donkeys.
Mejia-Pereira S; Perez-Ecija A; Buchanan BR; Toribio RE; Mendoza FJ
Equine Vet J; 2019 Jul; 51(4):481-488. PubMed ID: 30362589
[TBL] [Abstract][Full Text] [Related]
33. Equine pituitary pars intermedia dysfunction.
McFarlane D
Vet Clin North Am Equine Pract; 2011 Apr; 27(1):93-113. PubMed ID: 21392656
[TBL] [Abstract][Full Text] [Related]
34. The use of adrenocorticotrophic hormone as a potential biomarker of pituitary pars intermedia dysfunction in horses.
Lee ZY; Zylstra R; Haritou SJ
Vet J; 2010 Jul; 185(1):58-61. PubMed ID: 20537574
[TBL] [Abstract][Full Text] [Related]
35. The effects of sample handling and N-phenylmaleimide on concentration of adrenocorticotrophic hormone in equine plasma.
Rendle DI; Litchfield E; Gough S; Cowling A; Hughes KJ
Equine Vet J; 2015 Sep; 47(5):587-91. PubMed ID: 24980684
[TBL] [Abstract][Full Text] [Related]
36. Effect of early or late blood sampling on thyrotropin releasing hormone stimulation test results in horses.
Thane K; Uricchio C; Frank N
J Vet Intern Med; 2022 Mar; 36(2):770-777. PubMed ID: 35049089
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of suspected pituitary pars intermedia dysfunction in horses with laminitis.
Donaldson MT; Jorgensen AJ; Beech J
J Am Vet Med Assoc; 2004 Apr; 224(7):1123-7. PubMed ID: 15074858
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of plasma ACTH, alpha-melanocyte-stimulating hormone, and insulin concentrations during various photoperiods in clinically normal horses and ponies and those with pituitary pars intermedia dysfunction.
Beech J; Boston RC; McFarlane D; Lindborg S
J Am Vet Med Assoc; 2009 Sep; 235(6):715-22. PubMed ID: 19751169
[TBL] [Abstract][Full Text] [Related]
39. Diagnosis of equine pituitary pars intermedia dysfunction.
Stewart AJ; Ireland JL; Durham AE; McGowan CM
Vet J; 2023; 300-302():106036. PubMed ID: 37805159
[TBL] [Abstract][Full Text] [Related]
40. PITUITARY PARS INTERMEDIA DYSFUNCTION (EQUINE CUSHING'S DISEASE) IN NONDOMESTIC EQUIDS AT MARWELL WILDLIFE: A CASE SERIES. ONE CHAPMAN'S ZEBRA ( EQUUS QUAGGA CHAPMANI) AND FIVE PRZEWALSKI's HORSES ( EQUUS FERUS PRZEWALSKII).
Shotton JCR; Justice WSM; Salguero FJ; Stevens A; Bacci B
J Zoo Wildl Med; 2018 Jun; 49(2):404-411. PubMed ID: 29900762
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
